62 WAXES & BUTTERS 50% 40% B 30% C 20% 10% A 0% -10% -20% 15 Min Figure 3: Skin protection while shaving with Floraesters. 20%


n A Floraesters n B Petrolatum/Dimethicone n C Vehicle C


15% C 60 Min B C D D A


n A Vehicle n B Vehicle + 1.5% Floraesters K-100 Jojoba n C Vehicle + 3% Floraesters 30 n D Vehicle + 1.5% Floraesters K-100 Jojoba + 3% Floraesters 30


Providing skin barrier protection during shaving FE30 (3%) and K-100 (1.5%) were evaluated in combination and independently within a shaving cream compared to the vehicle (see Table 1) for reducing skin barrier disfunction after shaving. One application of each shaving cream test article was made to the lower legs of female subjects (n=15), followed by shaving, rinsing, and patting dry. TEWL evaluations were made using a Tewameter TM 300 (in duplicate) at baseline (pre-shave), and 15 and 60 minutes post-shave. The results appear in Figure 3. The data in Figure 3 show that the


inclusion of 3% FE30 and/or 1.5% K-100 enhanced skin barrier function (i.e. resulted in lower TEWL values) when used in a shaving cream. Both test articles containing FE30 produced statistically significantly (p<0.001) smaller increases (15 minutes) or larger decreases (60 minutes) in TEWL as compared to the vehicle test article. Additionally, the test article containing both FE30 and K-100 did not result in a statistically significant increase in TEWL 15 minutes post-shave, indicating the preservation of skin barrier function. Previous literature also supports these


10% B A A 5% B


results with regard to skin barrier disruption (as measured by TEWL). The inclusion of 2% FE20, FE30, or FE60 in a lotion (o/w emulsion) prevented disruption of the skin by SLS, and improved skin barrier function (p<0.001) better than the vehicle and performed statistically equivalently to the positive control (5% petrolatum).9


0% 25 hr Figure 4: Erythema reduced with Floraesters.


Table 1: Vehicle Formulations Shaving Cream Ingredient Water


Stearic Acid


Propylene Glycol Monostearate Butylene Glycol Glycerin


Glycol Stearate (and) Stearamide AMP


Aloe Barbadensis Leaf Juice Preservative


Triethanolamine


Magnesium Aluminum Silicate Polyquaternium-10 Tetrasodium EDTA Fragrance


PERSONAL CARE EUROPE Ointment


% wt./wt. Ingredient q.s.


12.50 3.50


2.00 2.00


1.00


1.00 1.00 0.50 0.40 0.30 0.20 0.20


Macadamia Integrifolia Seed Oil Glycerin


Ethyl Macadamiate


Glyceryl Behenate /Isostearate/Eicosadioate


Jojoba Oil/Macadamia Seed Oil Esters (and) Squalene (and) Phytosteryl Macadamiate (and) Phytosterols (and) Tocopherol


Trihydroxystearin


% wt./wt. q.s.


15.00 14.00


5.50 Helianthus Annuus (Sunflower) Seed Oil 4.00 4.00 2.80


Polyglyceryl-10 Behenate/Eicosadioate 1.20 Polyglyceryl-2 Dipolyhydroxystearate 1.00 Preservative Lactic Acid


0.60 q.s.


48 hr


Reducing surfactant-induced erythema A blend of FE20, FE30, and FE60 (26%) and K-100 (5%) were evaluated compared to a blend of petrolatum (30%) and dimethicone (1%) (known skin protectants) within an ointment formulation for mitigation of sodium lauryl sulfate (SLS) induced erythema, as compared to the vehicle (see Table 1). One application of each ointment test


article was made to the volar forearms of female subjects (n=13), followed by a 24-hour exposure to the skin irritant (0.3% SLS solution, under occlusion, using 19mm Hill Top Chambers with Webril). Erythema measurements using the Mexameter MX 1810


(in triplicate) were taken at baseline,


and 24 and 48 hours post-patch removal. The results appear in Figure 4. The data in Figure 4 show that the


inclusion of FE20, FE30, and FE60 and K-100 reduced erythema up to 70% compared to the vehicle and performed statistically equivalent to petrolatum and dimethicone. The inclusion of FE20, FE30, and FE60 and K-100 resulted in statistically significantly (p<0.05) less erythema than the vehicle 24 and 48 hours after patch


September 2020


Percent Change in TEWL (relative to baseline)


improving TEWL


increasing barrier disruption


% Change in Erythema - Mexmeter (relative to baseline)


increasing erythema


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92